SPONSORED:

Poll: 1 in 5 US adults report trouble affording prescription drugs

Poll: 1 in 5 US adults report trouble affording prescription drugs
© istock

About 1 in 5 U.S. adults say that they or someone in their household has been unable to afford drugs that were prescribed to them in the past 12 months, according to a new poll from Gallup and West Health. 

The survey found that 22.9 percent of U.S. adults said there had been a time in the past year when their household was unable to pay for drugs they were prescribed, up from 18.9 percent in January. 

ADVERTISEMENT

The poll illustrates the struggles many Americans have paying for medication at a time when lowering drug prices is an intense subject of debate in Washington. 

President TrumpDonald TrumpBiden prepares to confront Putin Biden aims to bolster troubled Turkey ties in first Erdoğan meeting Senate investigation of insurrection falls short MORE has railed against high drug prices and has proposed some steps, including linking certain Medicare drug prices to lower ones paid in other countries, but he has not taken any major action that has gone into effect yet. 

The Gallup survey finds the public is mostly negative on Trump’s performance on the issue so far, with 66 percent of adults saying he has done “not very much” or “none at all” to fight high drug prices. Twenty percent said he had done a “fair amount” and 7 percent said “a great deal.”

Speaker Nancy PelosiNancy PelosiPelosi: 'No intention' of abandoning Democrats' infrastructure goals Senate investigation of insurrection falls short Ocasio-Cortez: 'Old way of politics' influences Manchin's thinking MORE (D-Calif.) is pushing a sweeping bill to allow the secretary of Health and Human Services to negotiate lower prices on up to 250 drugs per year. Republicans oppose that measure, warning it would hinder the development of new treatments, but some are supporting smaller measures like a bill in the Senate from Sens. Chuck GrassleyChuck GrassleyHouse unveils antitrust package to rein in tech giants Iowa governor questions lack of notice on migrant children flights to Des Moines Senate crafts Pelosi alternative on drug prices MORE (R-Iowa) and Ron WydenRonald (Ron) Lee WydenNew Alzheimer's drug sparks backlash over FDA, pricing The Hill's Morning Report - Presented by Facebook - Bipartisan group reaches infrastructure deal; many questions remain Senate panel advances nominations for key Treasury positions MORE (D-Ore.). 

Drug companies say that the problem is insurers and pharmacy benefit managers who are not passing discounts they receive on to consumers.